Status:
RECRUITING
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Solid Tumours
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of th...
Eligibility Criteria
Inclusion
- inclusion criteria:
- Signed and dated written informed consent in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.
- Patients ≥18 years old or over the legal age of consent in countries where that is greater than 18 years at the time of signature of the Informed consent form (ICF).
- Documented (previously established by local testing) Human epidermal growth factor receptor 2 (HER2) status of:
- HER2 overexpression/amplification
- Known activating HER2 mutations
- Availability and willingness to provide a sample of archival formalin-fixed paraffin embedded (FFPE) tumour tissue material
- Patient with histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumour who has had at least one prior line of therapy for metastatic disease. In the opinion of the Investigator, patients must be unlikely to tolerate or derive clinically meaningful benefit from further standard of care therapy known to prolong survival.
- Further inclusion criteria apply.
- exclusion criteria:
- Diagnosis of HER2 mutant Non-small cell lung cancer (NSCLC) (except where there is co-existing presence of HER2 overexpression / amplification)
- Previous or concomitant malignancies other than the 1 treated in this trial within the previous 3 years except:
- effectively treated non-melanoma skin cancers
- effectively treated carcinoma in situ of the cervix
- effectively treated ductal carcinoma in situ of the breast
- localised prostate cancer on watchful waiting or active surveillance
- other effectively treated malignancy that is considered cured by local treatment.
- Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial
- Not completely recovered from major surgery (major according to the investigator's assessment) performed prior to screening or planned within 6 months after screening, e.g. hip replacement Further exclusion criteria apply.
Exclusion
Key Trial Info
Start Date :
October 11 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 29 2028
Estimated Enrollment :
430 Patients enrolled
Trial Details
Trial ID
NCT06581432
Start Date
October 11 2024
End Date
December 29 2028
Last Update
January 6 2026
Active Locations (74)
Enter a location and click search to find clinical trials sorted by distance.
1
Alaska Oncology and Hematology, LLC
Anchorage, Alaska, United States, 99508
2
University of Arizona Comprehensive Cancer Center
Tucson, Arizona, United States, 85719
3
Precision NextGen Oncology
Beverly Hills, California, United States, 90212
4
Scripps Cancer Center Torrey Pines
La Jolla, California, United States, 92037